SE9901007D0 - Use of fucosylated sialylated N-acetyl lactosamin carbohydrate structures for inhibition of bacterial adherence - Google Patents

Use of fucosylated sialylated N-acetyl lactosamin carbohydrate structures for inhibition of bacterial adherence

Info

Publication number
SE9901007D0
SE9901007D0 SE9901007A SE9901007A SE9901007D0 SE 9901007 D0 SE9901007 D0 SE 9901007D0 SE 9901007 A SE9901007 A SE 9901007A SE 9901007 A SE9901007 A SE 9901007A SE 9901007 D0 SE9901007 D0 SE 9901007D0
Authority
SE
Sweden
Prior art keywords
sialyl
inhibition
lewis
carbohydrate structures
fucosylated sialylated
Prior art date
Application number
SE9901007A
Other languages
English (en)
Swedish (sv)
Inventor
Thomas Boren
Lennart Hammarstroem
Karl-Anders Karlsson
Susann Teneberg
Original Assignee
Thomas Boren
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thomas Boren filed Critical Thomas Boren
Priority to SE9901007A priority Critical patent/SE9901007D0/xx
Publication of SE9901007D0 publication Critical patent/SE9901007D0/xx
Priority to AT00921217T priority patent/ATE249227T1/de
Priority to PCT/SE2000/000514 priority patent/WO2000056343A1/en
Priority to EP00921217A priority patent/EP1169044B1/de
Priority to JP2000606247A priority patent/JP2002539266A/ja
Priority to DE60005164T priority patent/DE60005164D1/de
Priority to AU41557/00A priority patent/AU4155700A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SE9901007A 1999-03-19 1999-03-19 Use of fucosylated sialylated N-acetyl lactosamin carbohydrate structures for inhibition of bacterial adherence SE9901007D0 (sv)

Priority Applications (7)

Application Number Priority Date Filing Date Title
SE9901007A SE9901007D0 (sv) 1999-03-19 1999-03-19 Use of fucosylated sialylated N-acetyl lactosamin carbohydrate structures for inhibition of bacterial adherence
AT00921217T ATE249227T1 (de) 1999-03-19 2000-03-16 Verwendung von fucosilierten sialilierten n- acetyl-lactosamin-kohlenhydratstrukturen zur hemmung der bakteriellen adhäsion
PCT/SE2000/000514 WO2000056343A1 (en) 1999-03-19 2000-03-16 Use of fucosylated sialylated n-acetyl lactosamine carbohydrate structures for inhibition of bacterial adherence
EP00921217A EP1169044B1 (de) 1999-03-19 2000-03-16 Verwendung von fucosilierten sialilierten n-acetyl-lactosamin-kohlenhydratstrukturen zur hemmung der bakteriellen adhäsion
JP2000606247A JP2002539266A (ja) 1999-03-19 2000-03-16 細菌接着を阻止するためのフコシル化シアリル化ｎ−アセチルラクトサミン炭水化物構造物の使用
DE60005164T DE60005164D1 (de) 1999-03-19 2000-03-16 Verwendung von fucosilierten sialilierten n-acetyl-lactosamin-kohlenhydratstrukturen zur hemmung der bakteriellen adhäsion
AU41557/00A AU4155700A (en) 1999-03-19 2000-03-16 Use of fucosylated sialylated n-acetyl lactosamine carbohydrate structures for inhibition of bacterial adherence

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9901007A SE9901007D0 (sv) 1999-03-19 1999-03-19 Use of fucosylated sialylated N-acetyl lactosamin carbohydrate structures for inhibition of bacterial adherence

Publications (1)

Publication Number Publication Date
SE9901007D0 true SE9901007D0 (sv) 1999-03-19

Family

ID=20414923

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9901007A SE9901007D0 (sv) 1999-03-19 1999-03-19 Use of fucosylated sialylated N-acetyl lactosamin carbohydrate structures for inhibition of bacterial adherence

Country Status (7)

Country Link
EP (1) EP1169044B1 (de)
JP (1) JP2002539266A (de)
AT (1) ATE249227T1 (de)
AU (1) AU4155700A (de)
DE (1) DE60005164D1 (de)
SE (1) SE9901007D0 (de)
WO (1) WO2000056343A1 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116466082A (zh) * 2023-04-23 2023-07-21 江南大学 幽门螺杆菌o2血清型o抗原糖片段在幽门螺杆菌感染检测装置制备中的应用

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002066502A1 (en) * 2001-02-21 2002-08-29 Boren Thomas Helicobacter pylori sialic acid binding adhesin, saba and saba - gene
ATE429233T1 (de) * 2001-06-29 2009-05-15 Glykos Finland Oy Verwendung mindestens einer glycoinhibitor- substanz gegen infektionskrankheiten
FI20011403A7 (fi) * 2001-06-29 2002-12-30 Carbion Oy Menetelmä ja koostumukset vatsan sairauksien hoitoon
JP2005532793A (ja) * 2002-04-22 2005-11-04 レコファーマ アーベー 微生物付着を阻害するための融合ポリペプチドおよび方法
FI20021989A0 (fi) * 2002-11-06 2002-11-06 Halina Miller-Podraza Korkean affiniteetin Helicobacter pylori-reseptorit ja niiden käyttö
EP2692740A1 (de) * 2012-07-30 2014-02-05 Le Centre National De La Recherche Scientifique Glycanzusammensetzungen, Verfahren zu deren Herstellung und deren Verwendungen als Arzneimittel
WO2024213778A2 (en) 2023-04-12 2024-10-17 Boren Thomas Methods for preventing the development of a gastric disease associated with helicobacter pylori infection without eradicating the infection and for the assessment of the risk of developing such disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK76193D0 (da) * 1993-06-25 1993-06-25 Astra Ab Kulhydratderivater
JP3179108B2 (ja) * 1994-03-02 2001-06-25 ネオーズ テクノロジーズ，インコーポレーテッド 胃潰瘍及び十二指腸潰瘍を治療及び阻止する方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116466082A (zh) * 2023-04-23 2023-07-21 江南大学 幽门螺杆菌o2血清型o抗原糖片段在幽门螺杆菌感染检测装置制备中的应用

Also Published As

Publication number Publication date
AU4155700A (en) 2000-10-09
DE60005164D1 (de) 2003-10-16
EP1169044A1 (de) 2002-01-09
WO2000056343A1 (en) 2000-09-28
ATE249227T1 (de) 2003-09-15
JP2002539266A (ja) 2002-11-19
EP1169044B1 (de) 2003-09-10

Similar Documents

Publication Publication Date Title
NO20024011L (no) Karbohydratformulering (prebiotisk hjelpemiddel) for å forbedre immunforsvaret
Stege et al. Antimicrobial activity of aqueous extracts of Larrea divaricata Cav (jarilla) against Helicobacter pylori
EP3326634A3 (de) Zusammensetzung zur anregung der darmflora in neugeborenen, die durch kayserschnitt geboren wurden
EA200701519A1 (ru) Живая аттенуированная ротавирусная вакцина для перорального введения
BR0009166A (pt) Vacina
UA89791C2 (ru) Пищевая композиция, которая содержит неусваиваемые олигосахариды, для лечения или профилактики инфекций респираторного тракта
BR0013814A (pt) Métodos de tratamentos de um paciente humano suscetìvel a ou diagnosticado com uma doença com anticorpos anti-erbb2, artigos industrializados, métodos de tratamentos de câncer em pacientes humanos e usos do anticorpo anti-erbb2
BR0206689A (pt) Combinação de probióticos, e, uso desta
BR0314511A (pt) Seleção e uso de bactérias de ácido lático para reduzir a inflamação causada por helicobater
IL173481A0 (en) Polysaccharide double-layer microcapsules as carriers for biologically active substance oral administration
DK1835939T3 (da) Meningokokkonjugatvaccination
BRPI0410341B8 (pt) conjugados de polissacarídeo-proteína derivatizados de meningococos multivalentes e vacina
AR035652A1 (es) Una composicion nutricional, util para combatir la infeccion en el tracto gastrointestinal causada por organismos tipo helicobacter, el uso de dicha composicion para la preparacion de medicamentos, o productos alimenticios y el procedimiento para preparar dicha composicion
SE9901007D0 (sv) Use of fucosylated sialylated N-acetyl lactosamin carbohydrate structures for inhibition of bacterial adherence
CA2382887A1 (en) Immunopotentiating compositions
ES2136206T3 (es) Composicion antibacteriana que contiene alfalactalbumina multimerica.
BRPI0410761A (pt) uso de leucina, e, composição para administração entérica a pacientes
Ofek et al. A bright future for anti-adhesion therapy of infectious diseases
BRPI0410374A (pt) composição farmacêutica que compreende valsartano
Niederman Strategies for the prevention of pneumonia
EP1532279A4 (de) Verfahren, zusammensetzung und kit für die antigenbindung von norwalk-ähnlichen viren
BR9811422A (pt) Processo para a inibição de hiperplasia celular de músculo liso vascular em um paciente humano ou em outro paciente animal de sangue quente necessitando de tal tratamento, uso de pelo menos um oligossacarìdeo sulfatado, e, composição farmacêutica ou veterinária para a inibição de hiperplasia celular de músculo liso vascular
BR0112035A (pt) peptìdeos antimicrobianos de novispirin
MD20060037A (ro) Metodă de tratament al hepatitei virale acute C
Isler Doxycycline-induced esopageal ulceration